Not medical advice
Content on lutetium-therapy — including text, images, graphics, and other materials — is for general informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician with any questions you may have about a medical condition or treatment.
No doctor-patient relationship
Using this website does not establish a doctor-patient relationship between you and Art of Healing Cancer (AOHC), lutetium-therapy, our medical reviewers, or our patient navigators. Patient navigators provide informational guidance only.
No diagnosis or prescription
We do not diagnose conditions, prescribe treatments, or provide medical opinions on specific cases. Eligibility for Lutetium therapy or any other treatment is determined by your treating oncologist based on your full clinical picture.
Brand name use
Pluvicto® and Lutathera® are registered trademarks of Novartis (and its affiliate Advanced Accelerator Applications). We refer to these therapies primarily by their generic names — Lutetium Lu-177 PSMA and Lutetium Lu-177 DOTATATE — because most Indian centers, including those we work with, prepare and administer these therapies as generic radiopharmaceuticals rather than the imported branded formulations. Our use of either generic or brand names is for educational identification and does not imply endorsement, sponsorship, or partnership.
Emergency situations
Individual results
Patient stories, trial data, and outcome statistics presented on this site describe specific cases or populations. They are not predictions of individual outcomes. Cancer treatment outcomes vary widely based on individual factors that only your medical team can assess.
Drug information
Information about specific therapies (Lutetium Lu-177 PSMA, Lutetium Lu-177 DOTATATE, and others) reflects current FDA-approved indications and published clinical evidence. Drug labels, indications, and dosing may change. Always verify with current prescribing information and your treating physician.
Off-label and investigational therapies
Some content discusses off-label use of approved drugs or investigational therapies in clinical trials. This is educational information only. Off-label and investigational therapies should only be used under qualified medical supervision, often through formal trial enrollment.
India-specific regulatory framework
We operate under applicable Indian regulatory frameworks including CDSCO drug regulations and the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954. Content reflects these standards. We make no exaggerated claims about the outcomes of Lutetium therapy for any cancer.
Cost information
Cost ranges presented are estimates based on reported pricing as of the page's last review date. Actual costs vary by patient situation, insurance coverage, specific center, and time of treatment. Always verify directly with the treatment center.
Reporting adverse events
If you experience an adverse event with Lutetium therapy in India, report it to CDSCO Pharmacovigilance at pvpi.compat@gov.in. For US patients, report to FDA MedWatch.
Limitation of liability
To the maximum extent permitted by law, AOHC, lutetium-therapy, and our reviewers and navigators are not liable for any direct, indirect, consequential, or other damages arising from use of this website or our services.
Last updated
15 May 2026